219725-67-4

Basic information

• Product Name: TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE
• Synonyms: 4-Azetidin-3-yl-piperazine-1-carboxylic acid tert-butyl ester;1-Boc-4-(azetidin-3-yl)piperazine;1-Boc-4-(azetidin-3-yl)piperazine 2HCl;TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE;1-N-Boc-4-azetidin-3-yl-piperazine
• CAS NO: 219725-67-4
• Molecular Formula: C12H23N3O2
• Molecular Weight: 241.33
• Mol File: 219725-67-4.mol

Chemical Properties

• Boiling Point: 337.3°C at 760 mmHg
• Flash Point: 157.8°C
• Appearance: /
• Density: 1.115
• Vapor Pressure: 0.000106mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.81±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE(219725-67-4)
• EPA Substance Registry System: TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE(219725-67-4)

Safety Data

• Hazard Codes: N
• Statements: 51/53
• Safety Statements: 61
• RIDADR: UN3077
• Hazardous Substances Data: 219725-67-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE is used as a pharmaceutical intermediate for the synthesis of various drug molecules. Its unique chemical structure allows it to be a key component in the development of new medications with potential therapeutic benefits.
Used in Organic Chemistry:
In the field of organic chemistry, TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE is utilized as a versatile building block for the synthesis of other organic compounds. Its reactivity and functional groups enable chemists to create a wide range of molecules with diverse applications.
Used in Research and Development:
TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE is employed in research and development settings to explore its potential applications and properties. Scientists and researchers use TERT-BUTYL 4-(AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE to investigate its chemical behavior, reactivity, and possible uses in various chemical reactions and processes.

InChI:InChI=1/C12H23N3O2/c1-12(2,3)17-11(16)15-6-4-14(5-7-15)10-8-13-9-10/h10,13H,4-9H2,1-3H3

Upstream product

• 178311-82-5 tert-butyl 4-(1-benzhydrylazetidin-3-yl)piperazine-1-carboxylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1245646-73-4 tert-butyl 4-(1-((benzyloxy)carbonyl)azetidin-3-yl)piperazine-1-carboxylate 

Relevant articles and documents

RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE

Bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-Raf), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds Raf, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Compound with degrading STAT3 enzyme and preparation method and pharmaceutical application thereof

The present invention relates to a compound represented by general formula (I) or a stereoisomer thereof. Use of deuterated, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystals, and intermediates and preparation methods, and in STAT3-related diseases such as tumors. B-L-K(I).

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

COVALENT INHIBITORS OF KRAS G12C

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Compounds of the formula (I): where X1, A, Ar1, X and R are as defined in the specification, and pharmaceutically-acceptable salts thereof, are new, and are useful as tachykinin inhibitors which act at the NK1, NK2and NK3receptors or a combination of two or more thereof.